Search or
𝛼SK
𝛼SKbullish
Argenx SE (ARGX US): Vyvgart Indication Expansion Triggers Rally; Can Competition Play Spoilsport?
477 Views30 Aug 2024 15:40
SUMMARY
- Argenx SE (ARGX US) won FDA approval for second indication of Vyvgart for chronic inflammatory demyelinating polyneuropathy (CIDP) in June. The approval triggered ~30% rally in the share price.
- Johnson & Johnson (JNJ US) is seeking FDA approval for nipocalimab for generalized myasthenia gravis (gMG). Approved in 2021, Vyvgart dominates the gMG market. In 1H24, Vyvgart fetched $876M revenue.
- Nipocalimab will compete with Vyvgart. However, Argenx has already created a niche for itself and will continue to sit on a prime position due to its first mover advantage.
Related Insights
More »Trending Collections
More »Trending Insights
More »- Hang Seng Indexes: Announcement Tomorrow; Potential Changes & Updated Flows
- Daiichi Sankyo Placement - US$1.2bn Deal but Momentum Isn’t the Best, Last Deal Didn’t Do Well
- First Pacific (142 HK) Is Fully Valued Here
- US Government May Acquire Equity Stakes in Samsung Electronics and TSMC
- HK-Listed Apparel & Footwear Screener Aug 2025: Lever Style (1346 HK) Conference Call
Top Unpaywalled Insights
More »- India-China Economic Relations: Navigating Massive Imbalances and Strategic Dependencies
- Kyivstar (KYIV US): Structural Long – From Ukraine’s Resilience to Renewal; Uklon Embedded Value
- How to Own Lenovo at a Discount: BUY Legend Holdings Corp (3396 HK)
- Institutions Are Coming for Bitcoin — UTXO’s Loren Asmus Explains How
- Curator's Cut: Singapore Unlocks Value, India’s Jewellery Caution & Taiwan's Top ETF's Rebalance
Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
- Unlock research summaries
- Follow top, independent analysts
- Receive personalised alerts
- Access Analytics, Events and more
Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.
Upgrade later to our paid plans for full-access.
or
Already have an account? Sign In Now
Discussions
(Paid Plans Only)
Top Quartile
Tina Banerjee
Global Healthcare Analyst
Price Chart(Sign Up to Access)
- Argenx SE (ARGX US): Vyvgart Indication Expansion Triggers Rally; Can Competition Play Spoilsport?30 Aug 2024
x